posaconazole and Neutropenia

posaconazole has been researched along with Neutropenia* in 3 studies

Other Studies

3 other study(ies) available for posaconazole and Neutropenia

ArticleYear
Efficacy of posaconazole as treatment and prophylaxis against Fusarium solani.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:3

    Invasive fusariosis is a highly aggressive fungal infection associated with high mortality in heavily immunocompromised patients. Although posaconazole is efficacious as salvage therapy against infections caused by Fusarium species, concerns remain regarding this agent in the setting of reduced potency. To evaluate the efficacy of posaconazole as treatment or prophylaxis against invasive fusariosis caused by Fusarium solani, we utilized a neutropenic murine model of disseminated disease. ICR mice were administered escalating doses of posaconazole (6.25, 12.5, 25, or 50 mg/kg of body weight twice daily [BID]) by oral gavage beginning 2 days prior to inoculation in the prophylaxis studies or beginning 12 h after inoculation as treatment. Therapy was continued until day 9 postinoculation, and animals were monitored off therapy until day 15 for survival. Fungal burden was assessed as CFU in the kidneys. A clear dose-response relationship was observed, as the highest dose of posaconazole (50 mg/kg) was the most effective in prolonging survival and reducing tissue fungal burden both as prophylaxis and as treatment. This dose response was associated with high posaconazole serum concentrations as measured by bioassay. However, the extent of efficacy was also dependent on the infecting inoculum, as greater increases in survival and reductions in fungal burden were observed with the lower inocula tested. In this model high dosages of posaconazole were effective as treatment and prophylaxis against disseminated fusariosis caused by F. solani.

    Topics: Animals; Antifungal Agents; Chemoprevention; Disease Models, Animal; Drug Resistance, Fungal; Fusarium; Humans; Kidney; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Mycoses; Neutropenia; Treatment Outcome; Triazoles

2010
Posaconazole mono- or combination therapy for treatment of murine zygomycosis.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:2

    We compared the efficacy of combination posaconazole-liposomal amphotericin B (LAmB) therapy to monotherapy with either drug in diabetic ketoacidotic or neutropenic mice with disseminated zygomycosis caused by Rhizopus oryzae. Combination therapy was no better than LAmB alone, and posaconazole monotherapy did not improve survival or reduce fungal burden versus placebo.

    Topics: Amphotericin B; Animals; Antifungal Agents; Brain; Diabetic Ketoacidosis; Dose-Response Relationship, Drug; Drug Combinations; Kidney; Liposomes; Male; Mice; Mice, Inbred BALB C; Neutropenia; Rhizopus; Triazoles; Zygomycosis

2009
Case of fatal Blastoschizomyces capitatus infection occurring in a patient receiving empiric micafungin therapy.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:12

    We report the first case, to our knowledge, of Blastoschizomyces capitatus infection occurring in a patient receiving empirical echinocandin therapy for neutropenic fevers. Clinicians should consider B. capitatus infection in those neutropenic patients who remain febrile despite echinocandin therapy or who develop yeast bloodstream infections while receiving an echinocandin.

    Topics: Aged; Antifungal Agents; Echinocandins; Fatal Outcome; Geotrichosis; Geotrichum; Humans; Lipopeptides; Male; Micafungin; Microbial Sensitivity Tests; Neutropenia

2009